Test Price
2,800 AED✅ Home Collection Available
CACNA1D Gene Analysis – Next-Generation Sequencing (NGS) for Primary Aldosteronism & Neurological Disorders
Executive Summary & Core Metrics
-
✓
Accuracy: >99.9% diagnostic sensitivity via ISO 15189-accredited next-generation sequencing for full gene analysis.
-
✓
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
-
✓
Post-Test Support: Telephonic clinical guidance to help interpret results and plan next steps.
-
✓
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
-
✓
Price: 2,800 AED (all-inclusive, no hidden charges).
-
✓
Turnaround Time: Results delivered within 3–4 weeks from sample receipt.
Test Overview & Methodology
The CACNA1D gene analysis employs next-generation sequencing (NGS) to detect pathogenic variants across all exons and splice-site junctions. This comprehensive assay is indicated for patients with suspected primary aldosteronism, early-onset seizure disorders, or progressive neurological abnormalities of unknown origin. Identifying the precise genetic cause enables targeted therapy, informs prognosis, and allows family cascade testing.
| Feature | Our Test (NGS Full Gene Sequencing) | Closest Alternative (Targeted Mutation Analysis) |
|---|---|---|
| Precision | >99.9% sensitivity for known and novel variants | Limited to pre-defined hotspots; misses rare mutations |
| Method | NGS full exonic and splice site analysis | PCR-based bi-directional Sanger sequencing of selected regions |
| Turnaround | Results in 3–4 weeks | 2–3 weeks (incomplete coverage may require reflex to NGS) |
| Coverage | Complete coding region (±20 bp intronic boundaries) | Only 2–3 hot-spot exons |
| Variant Types | SNVs, indels, copy number variants (CNVs up to 5 exons) | Only known point mutations |
Physician Insight & Safety Protocols
“Interpreting a CACNA1D result requires careful correlation with your personal and family medical history. Our consultant medical geneticist guides each patient through the clinical implications to ensure you feel informed and empowered, never overwhelmed.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Safety Advisory
Do not discontinue any prescribed medications without consulting your physician. Genetic test results complement, but do not replace, ongoing clinical management.
Exclusion Criteria
- Acute medical instability that prevents safe sample collection (e.g., severe hypotension, active seizure).
- Individuals unable to provide informed consent or without a legal guardian. Consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Emergency Red Flags – Seek Immediate ER Care
- Sudden, severe headache or visual disturbance.
- Chest pain, palpitations, or extreme hypertension unresponsive to medication.
- Generalised tonic-clonic seizures lasting more than 5 minutes or occurring in clusters without recovery.
Patient FAQ & Clinical Guidance
1. What does the CACNA1D gene test detect?
This NGS assay identifies disease-causing mutations in the CACNA1D gene associated with primary aldosteronism, early-onset seizures, and progressive neurological abnormalities. It provides a definitive molecular diagnosis to guide targeted therapy.
2. How should I prepare, and is genetic counselling required?
A pre-test genetic counselling session is mandatory to document your detailed family pedigree and medical history. No fasting or special preparation is needed.
3. What do my results mean, and what support is available?
A positive result confirms the diagnosis and helps tailor treatment. Negative or uncertain findings are reviewed with a clinician via our telephonic post-test guidance service, ensuring you understand the implications fully.
4. Can family members be tested?
Yes, cascade testing for at-risk relatives is recommended when a pathogenic variant is identified. Your genetic counsellor will coordinate family testing and provide interpretative support.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA) and complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling of your genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – for electronic health record and telemedicine safeguards.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – governing informed consent and clinical accountability.
Your data is encrypted, stored in ISO 27001-certified servers, and accessible only to authorised clinical personnel.
Clinical & Logistical Metadata
| Test Name | CACNA1D Gene Analysis (Full Gene Sequencing by NGS) |
| Price (AED) | 2,800 AED (all-inclusive) |
| Turnaround Time | 3–4 Weeks (from sample receipt) |
| Sample Type / Matrix | Whole Blood (EDTA tube) – VIP Mobile Phlebotomy & Cold-Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) – Full exonic and splice-site analysis with CNV detection |
| ICD-10-CM Code | E26.0, G40.9 |
| LOINC Code | 81247-9 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians